Tags

Type your tag names separated by a space and hit enter

Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Clin Endocrinol (Oxf). 2007 Jan; 66(1):103-9.CE

Abstract

BACKGROUND Women with polycystic ovary syndrome (PCOS) exhibit elevated serum advanced glycation end-products (AGE) compared with healthy subjects. Short-term administration of orlistat has been shown to reduce the postmeal increase in serum AGE levels in women with PCOS and in controls.

OBJECTIVE

To evaluate the long-term effect of orlistat and a low-calorie diet on serum AGE levels, and on the hormonal and metabolic profile of obese PCOS and normal women.

DESIGN

A clinical trial of 6 months of orlistat administration with an energy-restricted diet [basic metabolic rate (BMR) 600 kcal/day] in all subjects.

SUBJECTS

Twenty-nine women with PCOS [aged 27.52 +/- 5.77 years; body mass index (BMI) 35.43 +/- 5.31 kg/m(2)] and 18 controls (aged 32.06 +/- 5.64 years; BMI 36.39 +/- 6.47 kg/m(2)).

MEASUREMENTS

Serum AGE levels (U/ml), hormonal and metabolic profile.

RESULTS

PCOS and controls did not differ in BMI (P = 0.58), waist-to-hip ratio (WHR) (P = 0.44), fasting insulin concentration (P = 0.45) and glucose-to-insulin ratio (GIR) (P = 0.34). PCOS women exhibited statistically higher AGE (P < 0.001) and testosterone levels (P < 0.001) compared with controls. After 6 months of orlistat treatment, AGE levels showed a statistically significant decrease in both groups (PCOS: baseline 9.08 +/- 1.84, post-orlistat 8.56 +/- 1.95, P = 0.001; controls: baseline 5.02 +/- 0.62, post-orlistat 4.91 +/- 0.69, P = 0.03), independently of the BMI reduction in the PCOS group. A significant reduction was observed in BMI (PCOS: P < 0.001; controls: P < 0.001), WHR (PCOS: P = 0.002; controls: P = 0.04), fasting insulin (PCOS: P < 0.001; controls: P = 0.008), and testosterone concentrations in PCOS (P < 0.001). SHBG concentration (PCOS: P = 0.004; controls: P = 0.008) and GIR (PCOS: P < 0.001; controls: P = 0.03) were significantly increased. A significant improvement was also observed in insulin resistance indices post-treatment in both groups.

CONCLUSIONS

Our data suggest that orlistat has a beneficial effect in reducing elevated AGE levels and improving the hormonal and metabolic profile in women with PCOS after 6 months of treatment, independently of BMI changes.

Authors+Show Affiliations

Laiko Hospital, Medical School, University of Athens, Endocrine Section, First Department of Medicine, Athens, Greece. akandara@otenet.grNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

17201808

Citation

Diamanti-Kandarakis, Evanthia, et al. "Effect of Long-term Orlistat Treatment On Serum Levels of Advanced Glycation End-products in Women With Polycystic Ovary Syndrome." Clinical Endocrinology, vol. 66, no. 1, 2007, pp. 103-9.
Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66(1):103-9.
Diamanti-Kandarakis, E., Katsikis, I., Piperi, C., Alexandraki, K., & Panidis, D. (2007). Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology, 66(1), 103-9.
Diamanti-Kandarakis E, et al. Effect of Long-term Orlistat Treatment On Serum Levels of Advanced Glycation End-products in Women With Polycystic Ovary Syndrome. Clin Endocrinol (Oxf). 2007;66(1):103-9. PubMed PMID: 17201808.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. AU - Diamanti-Kandarakis,Evanthia, AU - Katsikis,Ilias, AU - Piperi,Christina, AU - Alexandraki,Krystallenia, AU - Panidis,Dimitrios, PY - 2007/1/5/pubmed PY - 2007/7/24/medline PY - 2007/1/5/entrez SP - 103 EP - 9 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 66 IS - 1 N2 - UNLABELLED: BACKGROUND Women with polycystic ovary syndrome (PCOS) exhibit elevated serum advanced glycation end-products (AGE) compared with healthy subjects. Short-term administration of orlistat has been shown to reduce the postmeal increase in serum AGE levels in women with PCOS and in controls. OBJECTIVE: To evaluate the long-term effect of orlistat and a low-calorie diet on serum AGE levels, and on the hormonal and metabolic profile of obese PCOS and normal women. DESIGN: A clinical trial of 6 months of orlistat administration with an energy-restricted diet [basic metabolic rate (BMR) 600 kcal/day] in all subjects. SUBJECTS: Twenty-nine women with PCOS [aged 27.52 +/- 5.77 years; body mass index (BMI) 35.43 +/- 5.31 kg/m(2)] and 18 controls (aged 32.06 +/- 5.64 years; BMI 36.39 +/- 6.47 kg/m(2)). MEASUREMENTS: Serum AGE levels (U/ml), hormonal and metabolic profile. RESULTS: PCOS and controls did not differ in BMI (P = 0.58), waist-to-hip ratio (WHR) (P = 0.44), fasting insulin concentration (P = 0.45) and glucose-to-insulin ratio (GIR) (P = 0.34). PCOS women exhibited statistically higher AGE (P < 0.001) and testosterone levels (P < 0.001) compared with controls. After 6 months of orlistat treatment, AGE levels showed a statistically significant decrease in both groups (PCOS: baseline 9.08 +/- 1.84, post-orlistat 8.56 +/- 1.95, P = 0.001; controls: baseline 5.02 +/- 0.62, post-orlistat 4.91 +/- 0.69, P = 0.03), independently of the BMI reduction in the PCOS group. A significant reduction was observed in BMI (PCOS: P < 0.001; controls: P < 0.001), WHR (PCOS: P = 0.002; controls: P = 0.04), fasting insulin (PCOS: P < 0.001; controls: P = 0.008), and testosterone concentrations in PCOS (P < 0.001). SHBG concentration (PCOS: P = 0.004; controls: P = 0.008) and GIR (PCOS: P < 0.001; controls: P = 0.03) were significantly increased. A significant improvement was also observed in insulin resistance indices post-treatment in both groups. CONCLUSIONS: Our data suggest that orlistat has a beneficial effect in reducing elevated AGE levels and improving the hormonal and metabolic profile in women with PCOS after 6 months of treatment, independently of BMI changes. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/17201808/Effect_of_long_term_orlistat_treatment_on_serum_levels_of_advanced_glycation_end_products_in_women_with_polycystic_ovary_syndrome_ DB - PRIME DP - Unbound Medicine ER -